Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 12/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.70 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.70 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.70 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.70 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7093265 | 1.00 | CCKBR (0.73) | CCKBRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4414693 | 1.00 | CCKBR (0.73) | CCKBRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8611094 | 0.91 | CCKBR (0.77) | CCKBRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7213625 | 0.90 | HDAC3 (0.73) | CCKBRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8608802 | 0.90 | HDAC3 (0.73) | CCKBRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29499518 | 0.89 | HDAC3 (0.75) | CCKBRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8617432 | 0.89 | HDAC3 (0.75) | CCKBRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29437013 | 0.89 | HDAC3 (0.75) | CCKBRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8611083 | 0.87 | CCKBR (0.74) | CCKBRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7092092 | 0.86 | HDAC3 (0.74) | CCKBRHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0951466-B1 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20050267150-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C | 2005-12-01 | — | — | US | disclosed |
| US-20050192269-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050192265-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2005-09-01 | — | — | US | disclosed |
| US-6906056-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ELAN PHARMACEUTICALS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040106598-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2004-06-03 | — | — | US | disclosed |
| US-6569851-B1 | Treating Alzheimer's disease | ELAN PHARMACEUTIALS, INC. | 2003-05-27 | — | — | US | disclosed |
| EP-1089980-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067221-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267150-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | CCKBR 218/4885HDAC3 3895/4885HDAC4 3495/4885 |
| US-20050192265-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | CCKBR 218/4885HDAC3 3895/4885HDAC4 3495/4885 |
| US-20040106598-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | CCKBR 254/4885HDAC3 3928/4885HDAC4 3553/4885 |
| US-20050192269-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | CCKBR 218/4885HDAC3 3895/4885HDAC4 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.